10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health Immunomic Therapeutics is listed as one of the Top 10 Maryland Vaccine Influencers in public health and Dr. ...
September 29, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation ...
September 23, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to ...
Cancer R&D 2020 Symposium ITI is proud to be participating in the 5th International Conference on Cancer Research and Drug Development 2020, a three-day symposium bringing cutting edge developments in ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D., ...
Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held ...
ITI Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM
Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBM ...
Register Now: Dr. Teri Heiland joins a panel discussion: Past, Present and Future of Immuno-oncology
REGISTER NOW Oncology Central powered by Future Science Group presents the panel discussion: Past, Present and Future of Immuno-oncology DATE: September 23, 2020 TIME: 10:00AM EDT/7:00AM PDT/15:00PM BST This panel ...
Poster Title: Glypican-3-LAMP: A novel DNA vaccine for liver cancer immunotherapy Presentation Date: August 17-18, 2020 3:30-5PM EST Download poster here.
ITI was chosen as one of DC Inno’s on Fire Winners for 2020 alongside Emergent Biosolutions, Novavax and Viela Bio. Check it out… https://www.americaninno.com/dc/50-on-fire/meet-dc-innos-2020-Inno-on-fire DC Inno is your source for ...
-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. & ...
ITI Enters into License Agreement with Ichor to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001
-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering ...